[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508384":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":72,"collaborators":76,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":26,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":26,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":26,"overallStatus":101,"whyStopped":26,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: severe CIP with the treatment of corticosteroids","ACTIVE_COMPARATOR","severe CIP with the treatment of corticosteroids",[13],"Drug: Corticosteroids",{"label":15,"type":16,"description":17,"interventionNames":18},"Cohort 2: severe CIP with the treatment of corticosteroids and Ruxolitinib","EXPERIMENTAL","severe CIP with the treatment of corticosteroids and Ruxolitinib",[19],"Drug: Corticosteroids and Ruxolitinib",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Corticosteroids","Initial dosage of corticosteroids is no less than predinisone 1mg\u002Fkg\u002Fd or other corticosteroids with equal equivalence",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Corticosteroids and Ruxolitinib","Initial dosage of corticosteroids is no less than predinisone 1mg\u002Fkg\u002Fd or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib",[15],[32,45,54,63],{"facility":33,"status":26,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":26},"Department of Respiratory Medicine, Peking Union Medical College Hospita","Beijing","Beijing Municipality","100730","China","CN",{"type":40,"coordinates":41},"Point",[42,43],116.39723,39.9075,{"lat":43,"lon":42},{"facility":46,"status":26,"city":47,"state":48,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":26},"The Affiliated hospital of Inner Mongolia Medical University","Hohhot","Inner Mongolia",{"type":40,"coordinates":50},[51,52],111.65222,40.81056,{"lat":52,"lon":51},{"facility":55,"status":26,"city":56,"state":57,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":26},"The second affiliated hospital of Nanchang University","Nanchang","Jiangxi",{"type":40,"coordinates":59},[60,61],115.85306,28.68396,{"lat":61,"lon":60},{"facility":64,"status":26,"city":65,"state":66,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":67,"geoPoint":71,"contacts":26},"Shanxi Bethune Hospital","Taiyuan","Shanxi",{"type":40,"coordinates":68},[69,70],112.56028,37.86944,{"lat":70,"lon":69},{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Wang mengzhao","Chief Director of Department of Respiratory and Critical Care Medicine",[77,79,81],{"name":78,"class":6},"Second Affiliated Hospital of Nanchang University",{"name":80,"class":6},"The Affiliated Hospital of Inner Mongolia Medical University",{"name":64,"class":6},"100508384","the-efficacy-and-safety-of-corticosteroids-in-combination-with-ruxolitinib-in-the-management-of-checkpoint-inhibitor-pneumonia-100508384",false,"NCT05899725","The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia","The Efficacy and Safety of Corticosteroids in Combination With Biological Agents in the Management of Severe Immune Related Adverse Events Cohort A: The Efficacy and Safety of Corticosteroids or Corticosteroids Combination With Ruxolitinib in Patients With Severe Checkpoint Inhibitor Pneumonia","Inclusion Criteria:\n\n1. 18 years old≤ Aged ≤80 years old.\n2. Diagnosis of malignancy.\n3. Malignant tumors initially treated with immune checkpoint inhibitors (antibodies targeting PD-1, PD-L1, CTLA-4, or new immune checkpoint inhibitors) in combination with or without chemotherapy.\n4. Diagnosis of grade 3 or 4 CIP: CIP severity at CTCAE grade 3 or 4.\n5. Patients who and whose family members understand the study protocol, are willing to participate in the study and could provide written informed consent.\n\nExclusion Criteria:\n\n1. Predicted life expectancy\\\u003C12 weeks.\n2. Any evidence of active or uncontrolled viral infection, including hepatitis B, hepatitis C and human immunodeficiency virus (HIV), or any clinical signs of bacterial, other viral, parasitic or fungal infection requiring treatment.\n3. malignancy progression.\n4. Patients with other serious complications that may affect safety or adherence judged by the investigator.\n5. Any significant clinical and laboratory abnormalities judged by investigator that affect the safety evaluation.\n6. Patients can't fully understand the study protocol, arrangement and other study-related elements.\n7. Patients with evidence of severe liver or kidney dysfunction judged by investigator unsuitable for enrolment.\n8. Women who are pregnant, breast feeding or unable to use effective contraception during the study period and for 3 months after the completion.\n9. Patients who cannot comply with study treatment and follow-up according to the trial protocol.","ALL","15 Years","80 Years",{"count":93,"type":94},60,"ACTUAL","INTERVENTIONAL",[97],"NA","This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of severe checkpoint inhibitor pneumonitis.",[100],"Severe Checkpoint Inhibitor Pneumonitis","COMPLETED","2026-07-27",{"date":104,"type":94},"2026-07-28",{"date":106,"type":94},"2023-04-14",{"date":108,"type":94},"2026-06-30",{"name":5,"class":6},4]